<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139705">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104882</url>
  </required_header>
  <id_info>
    <org_study_id>INTRAGO-I/II</org_study_id>
    <nct_id>NCT02104882</nct_id>
  </id_info>
  <brief_title>INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study</brief_title>
  <official_title>INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <authority>Germany: Federal Office for Radiation Protection</authority>
    <authority>Germany: Ethics Commission II of the Medical Faculty Mannheim</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma multiforme (GBM) is a disease with an extremely poor prognosis. Despite surgery
      and radiochemotherapy, the tumors are likely to grow back very quickly.

      Intraoperative radiotherapy (IORT) may improve local control rates while sparing healthy
      tissue (Giordano et al. 2014). IORT takes place before cranioplasty directly after gross (or
      subtotal) tumor resection. Several past studies on IORT for GBM conducted in Japan and Spain
      have yielded encouraging results (Sakai et al. 1989; Matsutani et al. 1994; Fujiwara et al.
      1995; Ortiz de Urbina et al. 1995).

      However, the full potential of the procedure is to date largely unexplored as most previous
      studies used forward-scattering (electron-based) irradiation techniques, which frequently
      led to inadequately covered target volumes. With the advent of the spherically irradiation
      devices such as the Intrabeam® system (Carl Zeiss Meditec AG, Oberkochen, Germany), even
      complex cavities can be adequately covered with irradiation during IORT. However, there is
      no data on the maximum tolerated dose of IORT with low-energy X-rays as generated by this
      system.

      The INTRAGO I/II study aims to find out which dose of a single shot of radiation, delivered
      intraoperatively direct after surgery, is tolerable for patients with GBM. A secondary goal
      of the study is to find out whether the procedure may improve survival rates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The maximum tolerated (single) dose of IORT with 50 kV X-rays will be assessed using a classical &quot;3+3&quot; design:
The first cohort of 3 patients will receive IORT with 20 Gy (prescribed to the applicator surface). If none of these patients experiences a DLT, another three patients will be treated at the next higher dose level (30 Gy). However, should a patient experience a DLT, 3 more patients will be treated at the same dose level. The dose escalation stops if two ore more patients in a cohort of 3-6 patients experience DLT.  The MTD is then defined as the dose level just below the toxic dose level.
Two types of DLT are defined:
Early DLT (≤ 3 weeks after IORT):
wound infections / wound healing difficulties requiring surgical intervention
IORT-related cerebral bleeding or ischemia
Delayed DLT (≤ 3 months after IORT):
Symptomatic brain necrosis requiring surgical intervention
Early termination of EBRT (before the envisaged dose of 60 Gy) due to radiotoxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Intraoperative Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)</intervention_name>
    <arm_group_label>Intraoperative Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed glioblastoma multiforme in frozen sections

          -  Age ≥50 years

          -  Karnofsky Performance Index ≥ 50%

          -  Informed consent

          -  Adequate birth control (e.g., oral contraceptives)

        Exclusion Criteria:

          -  Astrocytoma ≤ WHO grade III

          -  Gliomatosis cerebri

          -  Multifocal lesions

          -  Infratentorial localization

          -  Previous cranial radiation therapy (any location)

          -  Uncontrolled intercurrent illnesses including, but not limited to, ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Contraindications for general anaesthesia

          -  Bleeding or clotting disorders

          -  Contraindications for MRI or CT scans

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Wenz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Radiation Oncology, Universitätsmedizin Mannheim, University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Schmiedek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank A Giordano, MD</last_name>
    <phone>+49 621 383</phone>
    <phone_ext>6020</phone_ext>
    <email>frank.giordano@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Brehmer, MD</last_name>
    <phone>+49 621 383</phone>
    <phone_ext>2360</phone_ext>
    <email>stefanie.brehmer@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim, University of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank A Giordano, MD</last_name>
      <phone>+49 621 383</phone>
      <phone_ext>6020</phone_ext>
      <email>frank.giordano@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Matsutani M, Nakamura O, Nagashima T, Asai A, Fujimaki T, Tanaka H, Nakamura M, Ueki K, Tanaka Y, Matsuda T. Intra-operative radiation therapy for malignant brain tumors: rationale, method, and treatment results of cerebral glioblastomas. Acta Neurochir (Wien). 1994;131(1-2):80-90.</citation>
    <PMID>7709789</PMID>
  </reference>
  <reference>
    <citation>Ortiz de Urbina D, Santos M, Garcia-Berrocal I, Bustos JC, Samblas J, Gutierrez-Diaz JA, Delgado JM, Donckaster G, Calvo FA. Intraoperative radiation therapy in malignant glioma: early clinical results. Neurol Res. 1995 Aug;17(4):289-94.</citation>
    <PMID>7477745</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Frederik Wenz</investigator_full_name>
    <investigator_title>Director, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>High-Grade Glioma</keyword>
  <keyword>Malignant Glioma</keyword>
  <keyword>IORT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
